Zobrazeno 1 - 8
of 8
pro vyhledávání: '"C, Carlos Rivera"'
Autor:
Zerecero-Salazar, Brenda Carolina, Viniegra, María Eugenia Ibarrarán, Guerrero, Armando Gómez, La Rosa, Patricia Hernández-De, De Jesús González Guillén, Manuel, Maurice, Miguel Jorge Escalona, Or, Oreste Sardiñas Gómez, C, Carlos Rivera, Toruño, Pedro
The Climate Change (CC) subject is still questionable, but the assessment of vulnerability to extreme events is critical for a strategic use of public resources. The most recent example is the impacts of “Ingrid” and “Manuel” cyclones, which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e6aad4a9b0a39b9d1a7929c26dcdaaea
Autor:
Cárdenas-Rodríguez, Noemí1 (AUTHOR) noemicr2001@yahoo.com.mx, Carmona-Aparicio, Liliana1 (AUTHOR), Pérez-Lozano, Diana L.1,2 (AUTHOR), Ortega-Cuellar, Daniel3 (AUTHOR), Gómez-Manzo, Saúl4 (AUTHOR), Ignacio-Mejía, Iván5,6 (AUTHOR)
Publikováno v:
Molecular Medicine Reports. Apr2020, Vol. 21 Issue 4, p1685-1701. 17p.
Autor:
Begley, Charles, Wagner, Ryan G., Abraham, Annette, Beghi, Ettore, Newton, Charles, Kwon, Churl‐Su, Labiner, David, Winkler, Andrea S.
Publikováno v:
Epilepsia (Series 4); Apr2022, Vol. 63 Issue 4, p892-903, 12p
Publikováno v:
PLoS ONE. 1/27/2016, Vol. 11 Issue 1, p1-17. 17p.
Publikováno v:
2015 International Symposium on Lightning Protection (XIII SIPDA); 2015, p157-160, 4p
In this first edition, the book offers an updated, integral revision of the foundations in basic neuroimmunology; thoroughly exploring the molecular, clinical and intervention aspects applied to illnesses in this field; and presenting key information
Autor:
Erasmo Recami
'The Majorana Case is beautifully written, with a pleasant style, and concatenates a great deal of material. A text that could only be written by those who know the life and work of Ettore Majorana very well, as Prof Recami. The book traces the extra
Autor:
Luisa Rocha, Esper A. Cavalheiro
Although more than 10 new antiepileptic drugs have been developed in the past decade, epilepsy remains resistant to drug therapy in about one third of patients, many of whom struggle with the disease their entire lives. Managing these patients is a c